Zenobia partners with Alzheimer's Drug Discovery Foundation

Wednesday, August 15, 2012 11:54 AM

Zenobia Therapeutics, a fragment-based discovery company focused on central nervous system (CNS) disease based in San Diego, has formed a strategic partnership to provide Alzheimer's Drug Discovery Foundation (ADDF) researchers access to Zenobia's discovery platform.

Zenobia will provide ADDF researchers with complementary consultation to establish joint research plans that utilize the Zenobia platform and assist in preparation of grant proposals. Once funded, Zenobia will continue to work closely with researchers to evolve the plans as the program progresses. In addition, Zenobia will offer their premier Fragment Library 1 at a reduced price to ADDF researchers.

The Zenobia platform includes: a gene-to-structure platform with in-house cloning, expression and purification in E coli, insect and mammalian cells, a custom fragment library composed of diverse cores suitable for discovery of lead compounds that cross the blood-brain barrier, fragment screening by multiple validated methods and assay development (enzyme, cell and Drosophila). Zenobia will also provide access to their internal medicinal chemistry expertise to optimize the fragments to leads that are potent, selective and optimized for CNS ADME/PK properties.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs